# Weight-Loss Drug Linked to Fewer COVID Deaths – Research conducted at the Harvard T.H. Chan School of Public Health has found that individuals taking the weight-loss drug semaglutide had a lower risk of dying from COVID-19 compared to those not taking the drug. – The study examined data from over 5,000 patients with obesity who were hospitalized with COVID-19 and found that those taking semaglutide had a significantly lower risk of death. – Semaglutide is a medication used to treat obesity and type 2 diabetes. The findings suggest that this drug may have a protective effect against severe outcomes of COVID-19 in individuals with obesity. ## Harvard’s Research Findings – The research highlights the potential benefits of weight-loss medications beyond their primary purpose of aiding weight loss. – Patients taking semaglutide not only experienced weight loss but also had a reduced risk of severe COVID-19 outcomes, emphasizing the importance of managing obesity for overall health. ### Conclusion The study from the Harvard T.H. Chan School of Public Health sheds light on the potential link between the weight-loss drug semaglutide and improved outcomes in individuals with COVID-19. This research underscores the importance of weight management in promoting overall health and reducing the risk of severe complications from various health conditions. Contact Mindful Evolution to explore personalized weight-loss strategies for a healthier future. ***Weight Loss Disclaimer: Individual results may vary. Always consult with a healthcare provider before starting any weight-loss program.*** Contact Mindful Evolution on our website https://yourmindfulevolution.com or call or text us at 954-639-9960 to learn more about our telehealth services available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, Virginia.